[Acute promyelocytic leukemia: molecular aspects].
Acute promyelocytic leukemia is a key model system in Cancer biology. Its ability to differentiate upon exposure to retinoic acid constitutes the first example of differentiation therapy. The molecular basis of leukemogenesis is the PML/RAR fusion resulting from the t(15, 17) translocation. The fusion protein likely acts through interference with the function of nuclear receptors (resulting in a differentiation block) and also through interference with PML which appear to be a growth suppressor. The exquisite sensitivity of this disease to retinoic acid represents the first example of a therapy directly targeted at a specific and causative genetic lesion.
de Thé
H
H
CNRS UPR, 43, Hôpital Saint-Louis, Paris.
D002454:Cell Differentiation / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D007641:Keratolytic Agents / Q000494:pharmacology; D015473:Leukemia, Promyelocytic, Acute / Q000235:genetics / Q000378:metabolism*; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000378:metabolism; D014178:Translocation, Genetic; D014212:Tretinoin / Q000378:metabolism / Q000494:pharmacology
D007641:Keratolytic Agents; D011993:Recombinant Fusion Proteins; D014212:Tretinoin
La leucémie aiguë promyélocytaire: aspects moléculaires.